Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRYNOVIN vs CARISOPRODOL COMPOUND
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Brynoxin is a potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.
Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
Relief of discomfort associated with acute, painful musculoskeletal conditions,As an adjunct to rest, physical therapy, and other measures
Adult: 150 mg orally twice daily.
1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.
Terminal elimination half-life is 12 hours in patients with normal renal function; prolonged to 24-48 hours in moderate to severe renal impairment (Cr Cl < 30 m L/min).
Carisoprodol has a terminal elimination half-life of approximately 1.5–2 hours; its active metabolite meprobamate has a half-life of 9–12 hours, which may lead to prolonged effects with chronic use.
Primarily metabolized via glucuronidation by UGT1A9 and UGT2B7; minor metabolism by CYP3A4.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite). Aspirin is hydrolyzed by esterases in the liver and plasma to salicylic acid, which is further conjugated. Codeine is metabolized by CYP2D6 to morphine (active) and by CYP3A4 to norcodeine.
Renal excretion accounts for 70% of the administered dose as unchanged drug; biliary/fecal excretion accounts for 30%.
Carisoprodol is primarily metabolized in the liver, with about 50% excreted renally as unchanged drug and metabolites; the major metabolite meprobamate is also renally excreted. Fecal excretion is negligible (<2%).
85% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Carisoprodol is approximately 60% bound to plasma proteins, mainly albumin.
1.5 L/kg, indicating extensive tissue distribution and penetration into peripheral compartments.
Volume of distribution is approximately 0.6–0.8 L/kg, indicating distribution into total body water.
Oral: 75% (range: 60-90%) with minimal first-pass metabolism; intravenous: 100%.
Oral bioavailability is nearly complete (close to 100%) due to rapid and extensive absorption.
Cr Cl 30-59 m L/min: 75 mg twice daily; Cr Cl 15-29 m L/min: 50 mg twice daily; Cr Cl <15 m L/min or dialysis: 25 mg once daily.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild-moderate impairment; use caution.
Child-Pugh A: no adjustment; Child-Pugh B: 75 mg twice daily; Child-Pugh C: 50 mg twice daily.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment, reduce dose or increase interval; specific guidelines not established.
Children ≥12 years and ≥40 kg: 150 mg twice daily; <40 kg: 5 mg/kg/dose twice daily (max 150 mg/dose).
Not recommended for pediatric patients due to aspirin content and risk of Reye syndrome.
No specific dose adjustment, but monitor renal function; start at lower end of dosing range if renal impairment.
Initiate at lowest effective dose; monitor for CNS depression, falls, and aspirin-related bleeding. Avoid in patients ≥65 years due to risks of dizziness, sedation, and GI bleeding.
None.
None
Ketoacidosis: Monitor for signs of ketoacidosis, including euglycemic ketoacidosis,Lower limb amputation: Consider risk factors prior to initiation; monitor for signs of infection or ulceration
Risk of dependence, abuse, and withdrawal with carisoprodol and codeine,CYP2D6 ultrarapid metabolizers may have morphine toxicity from codeine,Reye's syndrome risk in children with viral illness (aspirin),GI bleeding risk with aspirin,Respiratory depression with codeine,Sedation and impaired motor function,Hepatic impairment,Renal impairment
Severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease on dialysis,History of serious hypersensitivity reaction to brynoxin or any excipient in the formulation
Hypersensitivity to carisoprodol, meprobamate, aspirin, codeine, or any component,Porphyria,Acute intermittent porphyria,Children with viral illness (aspirin) due to Reye's syndrome risk,Breastfeeding (codeine),Severe renal or hepatic impairment,GI bleeding or peptic ulcer disease (aspirin),Concurrent use of MAOIs or within 14 days,Respiratory depression (codeine)
Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition. Avoid alcohol as it may increase hepatotoxicity risk. Take with food to reduce gastrointestinal upset.
Avoid alcohol and grapefruit juice. Alcohol increases CNS depression and risk of hepatotoxicity. Grapefruit juice may inhibit metabolism, leading to increased levels and toxicity.
First trimester: Human data limited; animal studies show embryotoxicity at supra-therapeutic doses. Avoid unless benefit outweighs risk. Second trimester: No specific malformation signal; monitor fetal growth. Third trimester: Risk of neonatal adaptation syndrome (irritability, feeding difficulties) at delivery if used near term.
Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fetal harm if used during the first trimester due to possible neural tube defects based on limited reports. In the second and third trimesters, maternal use may cause neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) and respiratory depression if used near term. Carisoprodol is not recommended during pregnancy unless benefit outweighs risk.
Excreted in breast milk in low amounts (M/P ratio 0.2–0.4). Considered compatible with breastfeeding; monitor infant for sedation or gastrointestinal effects.
Carisoprodol is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2-4 based on small studies. An infant would receive a weight-adjusted dose of about 4-8% of the maternal dose, which may cause sedation, drowsiness, or irritability in the neonate. Breastfeeding is not recommended during carisoprodol use, especially in premature infants or those with hepatic impairment. If used, monitor infant for signs of CNS depression.
Due to increased volume of distribution and enhanced hepatic clearance in second and third trimesters, the dose may need to be increased by 20–40% to maintain therapeutic plasma concentrations. Therapeutic drug monitoring (trough levels) recommended every 2 weeks with target range 5–15 mcg/m L. Postpartum: reduce dose to pre-pregnancy level within first week.
No specific dosing adjustments for carisoprodol are established in pregnancy. However, due to increased plasma volume and altered hepatic metabolism in pregnancy, the drug's half-life may be reduced. Clinical monitoring for efficacy and maternal side effects (e.g., drowsiness, dizziness) is recommended. Use the lowest effective dose for the shortest duration. Consider avoidance of the compound formulation with aspirin or other NSAIDs, which have additional risks.
Monitor renal function and electrolytes before and during therapy. Use with caution in patients with pre-existing cardiac disease due to risk of QT prolongation. Adjust dose in hepatic impairment (Child-Pugh B or C). Contraindicated with strong CYP3A4 inducers.
Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential; use cautiously in patients with history of substance abuse. Combination with other CNS depressants (e.g., alcohol, benzodiazepines) increases sedation risk. Limit use to 2-3 weeks due to lack of efficacy beyond that and risk of dependence. Avoid in patients with porphyria because carisoprodol may be porphyrinogenic.
Take exactly as prescribed; do not skip doses or double up.,Avoid grapefruit and grapefruit juice during treatment.,Report any signs of infection, unusual bruising, or yellowing of skin or eyes.,Use effective contraception during treatment and for 3 months after last dose.,Do not drive if you experience dizziness or blurred vision.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants while taking this drug.,Take only as prescribed; do not increase dose or frequency. This drug has abuse potential.,Inform your doctor if you have a history of drug or alcohol abuse, seizures, or liver/kidney disease.,Do not use for longer than 2-3 weeks unless directed by your doctor.
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRYNOVIN vs CARISOPRODOL COMPOUND, answered by our medical review team.
BRYNOVIN is a Opioid Partial Agonist that works by Brynoxin is a potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.. CARISOPRODOL COMPOUND is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRYNOVIN and CARISOPRODOL COMPOUND depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRYNOVIN is: Adult: 150 mg orally twice daily.. The standard adult dose of CARISOPRODOL COMPOUND is: 1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRYNOVIN and CARISOPRODOL COMPOUND in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRYNOVIN is classified as Category C. First trimester: Human data limited; animal studies show embryotoxicity at supra-therapeutic doses. Avoid unless benefit outweighs risk. Second trimester: No specific malformation . CARISOPRODOL COMPOUND is classified as Category A/B. Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.